Close Menu

NEW YORK – Exagen said this week that it had closed its previously announced initial public offering of 4.14 million shares of its common stock at a public offering price of $14 per share.

The aggregate gross proceeds to Exagen from the offering were $58 million, before deducting underwriting discounts and commissions, and other offering expenses. The gross proceeds included an exercise by the underwriters of their option to purchase 540,000 additional shares. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.